Iosocitrate dehydrogenase inhibitors as precision medicine for acute myeloid leukemia

doi:10.3760/cma.j.issn.1007-1245.2023.10.010

International Medicine and Health Guidance News ›› 2023, Vol. 29 ›› Issue (10): 1375-1378.DOI: 10.3760/cma.j.issn.1007-1245.2023.10.010

• New Medical Advances • Previous Articles Next Articles

Iosocitrate dehydrogenase inhibitors as precision medicine for acute myeloid leukemia

Liu Wanyi, Guo Jianxin

Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China

Received:2023-03-19 Online:2023-05-15 Published:2023-05-16
Contact: Guo Jianxin, Email: 1787844063@qq.com

异柠檬酸脱氢酶抑制剂对急性髓性白血病的精准医疗

刘婉艺郭健欣

福建医科大学附属第二医院血液科，泉州　362000

通讯作者: 郭健欣，Email：1787844063@qq.com

Abstract

Abstract:

The treatment of acute myeloid leukemia (AML) has improved dramatically over the past decades, with the development of new drugs that target specific genetic mutations associated with the disease. One of these, iosocitrate dehydrogenase (IDH) inhibitors, has achieved significant efficacy for patients with IDH1 or IDH2 mutations. This article reviews the researches on IDH inhibitors as precision medicine for AML.

Key words:

Acute myeloid leukemia, IDH inhibitors, Precision medicine

摘要：

急性髓性白血病（AML）的治疗在过去几十年中有了显著改善，开发了针对与该疾病相关特定基因突变精准治疗的新药物。异柠檬酸脱氢酶（IDH）抑制剂作为其中之一，对具有IDH1或IDH2突变的患者有显著的疗效。本文就IDH抑制剂在AML的精准医疗方面的研究进行综述。

关键词:

急性髓系白血病, IDH抑制剂, 精准医疗

Liu Wanyi, Guo Jianxin.

Iosocitrate dehydrogenase inhibitors as precision medicine for acute myeloid leukemia [J]. International Medicine and Health Guidance News, 2023, 29(10): 1375-1378.

刘婉艺郭健欣.

异柠檬酸脱氢酶抑制剂对急性髓性白血病的精准医疗 [J]. 国际医药卫生导报, 2023, 29(10): 1375-1378.

References

[1] Newell LF, Cook RJ. Advances in acute myeloid leukemia [J]. BMJ, 2021, 375:n2026. DOI: 10.1136/bmj.n2026.
[2] Gil-Sierra MD, Briceño-Casado MP, Sierra-Sanchez JF. Ivosidenib and azacitidine in IDH1-mutated AML [J]. N Engl J Med, 2022, 386(26): 2535-2536. DOI: 10.1056/NEJMc2206489.
[3] Goodman AM, Mohyuddin GR, Prasad V. Ivosidenib and azacitidine in IDH1-mutated AML [J]. N Engl J Med, 2022, 386(26):2536. DOI: 10.1056/NEJMc2206489.
[4] Griffioen MS, de Leeuw DC, Janssen JJWM, et al. Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies [J]. Cancers (Basel), 2022, 14(14):3456. DOI: 10.3390/cancers14143456.
[5] Upadhyay VA, Brunner AM, Fathi AT. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: progress and future directions [J]. Pharmacol Ther, 2017, 177:123-128. DOI: 10.1016/j.pharmthera.2017.03.003.
[6] Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer [J]. Cancer Cell, 2018, 34(2):186-195. DOI: 10.1016/j.ccell.2018.04.011.
[7] DiNardo CD. Ivosidenib in IDH1-mutated acute myeloid leukemia [J]. N Engl J Med, 2018, 379(12): 1186. DOI: 10.1056/NEJMc1809507.
[8] Raimondi V, Ciotti G, Gottardi M, et al. 2-hydroxyglutarate in acute myeloid leukemia: a journey from pathogenesis to therapies [J]. Biomedicines, 2022, 10(6): 1359. DOI: 10.3390/biomedicines10061359.
[9] Schnittger S, Haferlach C, Ulke M, et al IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status [J]. Blood, 2010, 116(25):5486-5496. DOI: 10.1182/blood-2010-02-267955.
[10] Kats LM, Reschke M, Taulli R, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance [J]. Cell Stem Cell, 2014, 14(3):329-341. DOI: 10.1016/j.stem.2013.12.016.
[11] Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition [J]. Blood, 2015, 125(2): 296-303. DOI: 10.1182/blood- 2013-10-533604.
[12] Eckardt JN, Stasik S, Röllig C, et al. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome [J]. Blood Cancer J, 2023, 13(1): 18. DOI: 10.1038/s41408-023-00790-1.
[13] Bill M, Jentzsch M, Bischof L, et al. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation [J]. Blood Adv, 2023, 7(3): 436-444. DOI: 10.1182/bloodadvances.2021005789.
[14] Liu X, Gong Y. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia [J]. Biomark Res, 2019, 7: 22. DOI: 10.1186/s40364-019-0173-z.
[15] Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm [J]. Blood Cancer J, 2021, 11(6):107. DOI: 10.1038/s41408-021- 00497-1.
[16] Martelli MP, Martino G, Cardinali V, et al. Enasidenib and ivosidenib in AML [J]. Minerva Med, 2020, 111(5):411-426. DOI: 10.23736/S0026-4806.20.07024-X.
[17] Gu Y, Yang R, Yang Y, et al. IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis [J]. Blood, 2021, 137(7):945-958. DOI: 10.1182/blood.2020007075.
[18] Sasaki M, Knobbe CB, Munger JC, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics [J]. Nature, 2012, 488(7413):656-659. DOI: 10.1038/nature11323.
[19] Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia [J]. Blood, 2020, 135(7): 463-471. DOI: 10.1182/blood. 2019002140.
[20] Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study [J]. Blood, 2021, 137(13): 1792-1803. DOI: 10.1182/blood.2020007233.
[21] Bhatt A, Powell K, Prasad V. The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many? [J]. Transl Oncol, 2022, 25: 101523. DOI: 10.1016/j.tranon.2022.101523.
[22] DiNardo CD, Stein AS, Stein EM, et al. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia [J]. J Clin Oncol, 2021, 39(1): 57-65. DOI: 10.1200/JCO.20.01632.
[23] Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib [J]. Blood, 2019, 133(7): 676-687. DOI: 10.1182/blood-2018- 08-869008.
[24] Kunadt D, Stasik S, Metzeler KH, et al. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation [J]. J Hematol Oncol, 2022, 15(1):126. DOI: 10.1186/s13045-022-01339-8.
[25] Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia [J]. Nature, 2014, 506(7488): 328-333. DOI: 10.1038/nature13038.
[26] Yang R, Zhao Y, Gu Y, et al. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma [J]. Oncogene, 2020, 39(40):6340-6353. DOI: 10.1038/s41388-020-01439-0.
[27] Norsworthy KJ, Mulkey F, Scott EC, et al. Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis [J]. Clin Cancer Res, 2020, 26(16): 4280-4288. DOI: 10.1158/1078-0432.CCR-20-0834.
[28] Stubbins RJ, Karsan A. Differentiation therapy for myeloid malignancies: beyond cytotoxicity [J]. Blood Cancer J, 2021, 11(12):193. DOI: 10.1038/s41408-021-00584-3.
[29] Norsworthy KJ, Luo L, Hsu V, et al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation [J]. Clin Cancer Res, 2019, 25(11): 3205-3209. DOI: 10.1158/1078-0432.CCR-18-3749.
[30] Zarei M, Hue JJ, Hajihassani O, et al. Clinical development of IDH1 inhibitors for cancer therapy [J]. Cancer Treat Rev, 2022, 103:102334. DOI: 10.1016/j.ctrv.2021.102334.

Iosocitrate dehydrogenase inhibitors as precision medicine for acute myeloid leukemia

异柠檬酸脱氢酶抑制剂对急性髓性白血病的精准医疗

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics